DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $12.3333.

A number of analysts have weighed in on DMAC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, January 21st. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a research report on Friday, November 14th. They issued an “overweight” rating on the stock. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Finally, Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

DiaMedica Therapeutics Price Performance

Shares of DMAC opened at $7.95 on Wednesday. DiaMedica Therapeutics has a 1 year low of $3.19 and a 1 year high of $10.42. The company has a market capitalization of $414.04 million, a price-to-earnings ratio of -11.20 and a beta of 1.09. The business has a 50-day moving average of $8.20 and a 200-day moving average of $7.57.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Cooperman Leon G boosted its position in shares of DiaMedica Therapeutics by 98.2% during the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares in the last quarter. Millennium Management LLC bought a new stake in DiaMedica Therapeutics in the third quarter worth approximately $8,157,000. Geode Capital Management LLC increased its holdings in DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture lifted its stake in DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after buying an additional 225,000 shares during the period. Finally, Royal Bank of Canada lifted its stake in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after buying an additional 154,701 shares during the period. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.